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Objectives: The aim of present study was to find genetic pathways activated during
infection with bacterial meningitis (BM) and potentially influencing the course of the
infection using genome-wide RNA expression profiling combined with pathway analysis
and functional annotation of the differential transcription.
Methods: We analyzed 21 patients with BM hospitalized in 2008. The control group
consisted of 18 healthy subjects. The RNA was extracted from whole blood, globin mRNA
was depleted and gene expression profiling was performed using GeneChip Human Gene
1.0 ST Arrays which can assess the transcription of 28,869 genes. Gene expression profile
data were analyzed using Bioconductor packages and Bayesian modeling. Functional
annotation of the enriched gene sets was used to define the altered genetic networks.
We also analyzed whether gene expression profiles depend on the clinical course
and outcome. In order to verify the microarray results, the expression levels of ten
functionally relevant genes with high statistical significance (CD177, IL1R2, IL18R1,
IL18RAP, OLFM4, TLR5, CPA3, FCER1A, IL5RA, and IL7R) were confirmed by quantitative
real-time (qRT) PCR.
Results: There were 8569 genes displaying differential expression at a significance level
of p < 0.05. Following False Discovery Rate (FDR) correction, a total of 5500 genes
remained significant at a p-value of < 0.01. Quantitative RT-PCR confirmed the differential
expression in 10 selected genes. Functional annotation and network analysis indicated that
most of the genes were related to activation of humoral and cellular immune responses
(enrichment score 43). Those changes were found in both adults and in children with
BM compared to the healthy controls. The gene expression profiles did not significantly
depend on the clinical outcome, but there was a strong influence of the specific type of
pathogen underlying BM.
Conclusion: This study demonstrates that there is a very strong activation of immune
response at the transcriptional level during BM and that the type of pathogen influences
this transcriptional activation.
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INTRODUCTION
Despite the availability of effective antibiotics, health care and
advances in adjunctive therapies, bacterial meningitis (BM) is still
one of the top 10 causes of infection related mortality worldwide.
Fatality rates as high as 20% for pneumococcal meningitis and 7%
for meningococcal meningitis are reported. Among the survivors,
30–50% have permanent neurological sequelae (Weisfelt et al.,
2006; Chaudhuri et al., 2008). Therefore, better understanding
of the pathophysiological processes and the host’s acute inflam-
matory response could ameliorate treatment and management
of BM.
Bacterial invasion into the cerebrospinal fluid (CSF) induces
a rapid inflammatory response, which is mediated by the innate
immune system. Microglia and astrocytes are equipped with
germline-encoded receptors, termed pattern-recognition recep-
tors (PRRs), which have evolved to recognize highly conserved
antigens, the so-called PAMPs (pathogen-associated molecular
patterns) (Konat et al., 2006). PRRs include the family of Toll-like
receptors (TLRs), of which TLR2 is the most important media-
tor of the inflammatory response to Gram-positive and TLR4 to
Gram-negative infection including BM (Koedel et al., 2003; Konat
et al., 2006; Neher and Brown, 2007). Many proinflammatory
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cytokines are released early into the circulation in response to sep-
sis or systemic inflammation. In cases of meningitis, cytokines,
and adhesion molecules released by peripheral immune organs
in the bloodstream cross the altered blood-CSF barrier and con-
tribute to their CSF levels (Trojano et al., 1996; Fassbender et al.,
1997).
The inflammatory response to bacterial invasion as a sys-
temic reaction has been studied in clinical trials investigating
sepsis on numerous occasions. The prevailing theory is that
the host’s response during sepsis, and likely also in BM, repre-
sents a pathological inflammatory response and therefore causes
more damage than the pathogen itself (Bone et al., 1992; Stone,
1994; Warren, 1997; Hotchkiss and Karl, 2003; Deisenhammer
et al., 2006). However, it is not known whether this patho-
logical inflammatory response is triggered by transcriptional
changes and whole genome expression profiling, to the best
of our knowledge, has not been performed in BM patients to
date.
The aim of our study was to identify up- or down-
regulated transcriptional pathways during the acute phase
of BM in RNA extracted from whole blood using whole
genome transcriptional profiling combined with pathway anal-
ysis and functional annotation. In addition, we analyzed the
possible factors (type of pathogen and outcome of the dis-
ease) associated with the gene expression profile in patients
with BM.
METHODS
STUDY PARTICIPANTS
The study was conducted in the Tallinn Children’s Hospital, the
North Estonian Medical Centre, the Tartu University Hospital,
the West Tallinn Central Hospital and the East Tallinn Central
Hospital between the 1st of January and the 31st of December
2008 and included 21 patients with culture proven BM and 18
healthy controls. The healthy control group consisted of medi-
cal personnel and was free of any acute infection and had not
taken any antibiotics within the month prior to blood sam-
pling. BM was diagnosed if in addition to clinical signs of BM,
there was a positive CSF culture of meningitis causing bacte-
ria and/or positive blood culture in presence of CSF pleocyto-
sis ≥10× 106 cells/L and/or positive CSF latex agglutination test
with pleocytosis ≥500× 106 cells/L. On admission, all patients
underwent a full clinical laboratory screening including a head
computed tomography (CT). All microbiological analyses were
performed according to the Clinical and Laboratory Standards
Institute (CLSI) criteria in the local hospital laboratories.
The patients’ outcome was evaluated by a neurologist at
discharge from the hospital as favorable (normal, 13 patients)
or poor outcome (with different complications, six patients),
based on objective neurologic examination. Neurologic sequelae
included cranial nerve disorders, paresis, ataxia, aphasia, cogni-
tive impairment, apallic state, and epileptic seizures (Table 1). In
two cases, the patients died following infection with BM.
Table 1 | Characteristics of the study population.
ID Age Previous Laboratory values Causative Outcome
antibiotics organism
Blood WBC CRP(mg/L) CSF WBC CSF
(109 cells/L) (109 cells/L) Protein g/L
M028 22 days No 8.7 147 13.4 2.1 S. agalactiae Epileptic syndrome
M039 17 days No 4.1 87 5.1 2.5 E.coli Normal
M031 55 years No 8.1 219 1.5 10.1 S. pneumoniae Died
M032 75 years Yes 21.8 251 7.7 1.7 S. pneumoniae Spastic tetraparesis
M027 52 years No 32.2 77 0.3 7.5 S. pneumoniae Aphasia, right spastic hemiparesis
M022 54 years No 9.6 171 1.2 2.6 S. pneumoniae Normal
M041 46 years No 26.3 5 0.07 0.5 S. pneumoniae Died
M046 13 years No 18.6 109 4.6 2.3 S. pneumoniae Normal
M040 73 years No 18.4 231 1.8 1.8 L. monocytogenes Normal
M029 37 years Yes 24.2 197 2.3 2.0 S. pneumoniae Normal
M004 57 years No 13.4 63 4.5 2.7 H. influenzae Normal
M014 58 years No 9.7 54 2.3 9.8 S. pneumoniae Cognitive dysfunction, anisocoria,
left spastic hemiparesis
M023 70 years Yes 11.4 174 4.3 6.6 S. pneumoniae Normal
M047 75 years No 34.6 146 0.04 0.6 S. pneumoniae Cognitive dysfunction
M036 17days No 2 105 0.2 6.9 S. agalactiae Normal
M042 71 years No 20.4 421 0.3 1.5 S. pneumoniae Normal
M025 47 years No 5.8 285 1.1 0.4 N. meningitidis C Facial nerve paresis, ataxia
M012 6 years No 4.3 19 0.06 2.9 S. pneumoniae Normal
M002 7 years No 21.9 109 1.7 4.6 N. meningitidis Normal
M006 55 years No 11.2 321 3.4 5.8 S. pneumoniae Normal
M038 60 years No 16.2 15 0.7 7.4 S. pneumoniae Normal
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Additional comparisons were made in order to assess whether
there was a relationship between gene expression profiles and the
specific pathogens mediating BM and/or the clinical outcome in
the patients. Comparisons were made between three pathogen
groups—(A1) pneumococci, (A2) other bacteria and (A3) con-
trols. Clinical outcome was divided into (B1) favorable outcome
without sequelae, (B2) poor outcome with neurologic sequelae or
death and (B3) healthy controls.
SAMPLE COLLECTION AND RNA PREPARATION
For RNA expression analysis, 6ml blood was collected via
venipuncture into Tempus tubes (Applied Biosystems, Foster
City, USA) within 48 h of admission, and stored first at −20◦C
for a maximum of 3–4 months, then transported in dry ice.
After thawing, RNA was extracted from whole blood according to
the manufacturer’s protocol (Applied Biosystems PN 4379228C).
Alpha and beta globin mRNA was depleted with the GlobinClear
Whole Blood Globin Reduction kit (Ambion, Austin, USA). The
quality of RNA was checked with a Bioanalzer 2100 (Agilent,
Santa Clara, USA) and gene expression profiling was performed
with GeneChip Human Gene 1.0 ST Arrays (Affymetrix, Santa
Clara, USA), which can measure the transcription of 28,869
genes.
MICROARRAY HYBRIDIZATION AND ANALYSIS
The RNA was labeled using the Affymetrix GeneChip Whole
Transcript (WT) Sense Target Labeling Assay (Affymetrix, Santa
Clara, USA). This assay is designed to generate amplified
and biotinylated sense-strand targets from the entire expressed
genome without bias. Briefly, double-stranded complementary
DNA (cDNA) was synthesized from 300 ng of total RNA by
reverse transcription using random hexamers tagged with a T7
promotor primer sequence. The double-stranded cDNA was
subsequently used as a template and amplified by T7 RNA
polymerase producing several copies of antisense complemen-
tary RNA (cRNA). In the second cycle of cDNA synthesis,
random hexamers were used to prime reverse transcription
of the cRNA from the first cycle to produce single-stranded
DNA in the sense orientation. This DNA was fragmented
with a combination of uracil DNA glycosylase (UDG) and
apurinic/apyrimidinic endonuclease 1 (APE 1). DNA was labeled
by terminal deoxynucleotidyl transferase (TdT) and hybridiza-
tion was performed according to the manufacturer’s protocol.
The arrays were subsequently washed, stained with phycoerythrin
streptavidin and scanned according to standard Affymetrix pro-
tocols. Images were processed using the Affymetrix Microarray
Suite 5.0 Expression Console and image quality subsequently
assessed. The processed data files were further analyzed using
Bioconductor affy and limma packages. Gene expression data (.cel
files) and study design information has been uploaded to the
public database Gene Expression Omnibus (accession number
GSE40586).
QUANTITATIVE REAL-TIME PCR (qRT-PCR) ANALYSIS
In order to verify the microarray results, genes from the gene
expression profiling were sorted according to the degree of sta-
tistical significance of the differential expression. Ten genes with
the lowest p-values were selected and further analyzed with
qRT-PCR: CD177, IL-1R2, IL-18R1, IL-18RAP, OLFM4, TLR5,
CPA3, FCER1A, IL5RA, and IL7R. RNAwas converted into cDNA
using High Capacity cDNA Synthesis kit fromApplied Biosystems
(4368814). TaqMan assays and Gene Expression Master mix was
used for the qRT-PCR reaction generated in the SDS 7900 HT
system (Applied Biosystems, CA, USA).
FUNCTIONAL ANNOTATION OF DIFFERENTIALLY EXPRESSED GENES
The Functional Analysis of a gene network is used to iden-
tify the biological functions that are most significantly related
to the molecules in the network. To define the functional net-
works of differentially expressed genes, data was analyzed by
using the Ingenuity Pathway Analysis (IPA, Ingenuity Systems,
www.ingenuity.com) that calculates a significance score (network
score) for each network. This score indicates whether the like-
lihood that the assembly of a set of focus genes in a network
could be explained by random chance alone (e.g., score of 2 indi-
cates that there is a chance of 1 in 100 that the focus genes are
together in a network due to random chance). A data set contain-
ing the Affymetrix probeset identifiers and their corresponding
fold change (log2) values were uploaded into the IPA software.
Each gene identifier was mapped to its corresponding gene object
in the Ingenuity Pathways Knowledge Base to identify molecules
whose expression was significantly differentially regulated (focus
genes or Networks Eligible molecules). These focus genes were
overlaid onto a global molecular network developed from infor-
mation contained in the Ingenuity Knowledge Base. Networks of
these focus genes were then algorithmically generated based on
their connectivity.
A network is a graphical representation of the molecular rela-
tionships between genes or gene products, which are represented
as nodes, and the biological relationship between two nodes is
represented as an edge (line). All edges are supported by at least
one reference from the literature, or from canonical information
stored in the Ingenuity Pathways Knowledge Base.
STATISTICAL ANALYSIS
The normalized, background subtracted and modeled expres-
sion (Robust Microarray Analysis, RMA) data was further ana-
lyzed using Bayesian model moderated t-test implemented in the
Bioconductor limma package of the statistical software R (http://
www.r-project.org/) (Smyth, 2004). False Discovery Rate (FDR)
was used to adjust p-values and to correct for the multiple testing
issues (Storey and Tibshirani, 2003). Comparisons between the
groups by pathogens and clinical outcome were performed, using
general linear models of analysis of variance (ANOVA), to test the
effect of these factors on gene expression pattern. Sample com-
parisions for the qRT-PCR reaction data were made using Welch’s
t-test.
The Ethics Review Committee on Human Research of the
University of Tartu approved the study. All subjects or their legal
representatives signed the informed consent.
RESULTS
The details of study patients are presented in Table 1. There
were 21 patients (median age 54 years, IQR 13, 60; 12 males),
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and 18 healthy controls (median age 54 years, IQR 47, 60; 5
males). Two patients died, neurological sequelae were observed
in six patients, and the remaining 13 patients had a normal
outcome. Altogether 14 patients had a pneumococcal infection,
two patients had a group B streptococcus (GBS) infection, and
another two patients had meningococcal meningitis. Escherichia
coli, Haemophilus influenzae, and Listeria monocytogenes were
found in one patient.
GENOME-WIDE EXPRESSION PROFILING
Comparison of the blood RNA samples isolated from BM patients
and healthy controls revealed distinct gene expression profiles.
Altogether 5500 genes out of the analyzed 28,869 genes showed
statistically significant differential expression at the FDR adjusted
p-values ≤0.01. Relative differences in the expression signal (fold
change or logFC) between these two groups were of moder-
ate effect size. In the BM patients, 47 genes were up-regulated
more than 1.5 fold and 93 down-regulated more than 1.5 fold,
compared to controls. In addition, the high B-statistics values
for the list of genes were indicative of genuine biological differ-
ences between these groups (Table 2). As it appears from the gene
annotations, most of these genes were related to immune regula-
tion and the anaphylactic response (e.g., FCER1A, CPA3, MS4A2;
Tables A1, A2).
GENE EXPRESSION PATTERN BM vs. CONTROLS
Heatmap (Figure 1) and a volcano plot (Figure 2) illustrate
the general gene expression pattern in relation to the main
factor—diagnosis of BM. The heatmap indicates a good cluster-
ing of samples according to whether the infection was present
or absent. There is a clear distinction between these two groups
and the gene expression profiles were able to discriminate
between the two main groups (Figure 1). The volcano plot
illustrates a high number of statistically significant differences
(p < 10e-06 is the equivalent for Bonferroni corrected p < 0.05)
(Figure 2). Moreover, the ratio of the differential expression
(fold change, illustrated in the abscissa of the volcano plot) is
also quite remarkable. Therefore, there was very good corre-
lation between the fold change differences and p-values (i.e.,
genes with a large fold change difference also had a low p-
value in the group-wise comparison). Two vertical axes denote
the position of a 1.5 and −1.5 fold change difference in the
gene expression profiles between disease cases and controls
(Figure 2).
In Table 1, the patients are lined up the same order as in
the heatmap (Figure 1). With two exceptions, the BM patients
and controls are clearly separated as they have very distinct gene
expression profiles. The two exceptions clustering within controls
(M028 and M039) were both neonates one with E. coli and the
other with GBS meningitis.
Additional statistical modeling was performed to assess
whether the type of pathogen or the outcome of the disease influ-
enced the gene expression profiles measure in the patient group.
Two separate linear models in which the gene expression differ-
ences were analyzed for the general effect of clinical outcome
[R code: design←model.matrix (∼0 + eset$outcome)] or for
the general effect of pathogen [R code: design←model.matrix
(∼0 + eset$bacteria)]. Subjects were allocated to one of three
pathogen groups: infected with S. pneumoniae; infected with
other pathogens; controls (non-infected). After general modeling
Table 2 | Twenty most significantly up- or down-regulated genes.
Probeset Sym LogFC AveExpr T P-value Adjusted B-value Gene name
P-value
7906443 FCER1A 2.48 6.42 12.04 4.51E-15 1.46E-10 23.77 Receptor for Fc fragment of IgE, alpha
polypeptide
8083260 CPA3 1.66 5.35 10.24 6.77E-13 1.09E-08 19.08 Carboxypeptidase A3 (mast cell)
7940226 MS4A2
(FCER1B)
1.19 4.94 9.62 4.22E-12 3.12E-08 17.35 Receptor for Fc fragment of IgE, beta
polypeptide
7971950 DACH1 −1.54 7.03 −9.58 4.81E-12 3.12E-08 17.23 Dachshund homolog 1
8048847 HRB −1.51 11.13 −9.49 6.30E-12 3.12E-08 16.97 HIV-1 Rev binding protein (AGFG1)
7988672 HDC 1.35 6.26 9.47 6.68E-12 3.12E-08 16.92 Histidine decarboxylase
8139656 GRB10 −2.33 7.87 −9.44 7.35E-12 3.12E-08 16.83 Growth factor receptor-bound protein 10
8151512 PAG1 −1.17 9.83 −9.42 7.73E-12 3.12E-08 16.78 Csk-binding protein
8103094 NR3C2 1.09 6.07 9.28 1.19E-11 4.27E-08 16.37 Mineralocorticoid receptor
8129618 VNN1 −2.98 10.04 −9.15 1.77E-11 5.33E-08 15.99 Vanin 1
8169249 MID2 0.95 5.71 9.14 1.82E-11 5.33E-08 15.97 Midline 2
7956878 IRAK3 −1.98 10.44 −9.09 2.11E-11 5.62E-08 15.82 Interleukin-1 receptor-associated kinase 3
8106626 NA −1.30 7.04 −9.07 2.26E-11 5.62E-08 15.76
8169154 NA −1.33 6.29 −9.01 2.68E-11 5.95E-08 15.60
8105579 IPO11 −1.58 5.35 −9.00 2.76E-11 5.95E-08 15.57 Importin 11
7980381 TMED8 −1.25 8.43 −8.98 2.95E-11 5.96E-08 15.51 Transmembrane emp24 protein
8112896 ANKRD34B −2.12 6.34 −8.83 4.75E-11 9.03E-08 15.05 Ankyrin repeat domain 34B
8103399 PDGFC −1.52 7.69 −8.77 5.70E-11 1.02E-07 14.88 Platelet derived growth factor C
8044035 IL18R1 −2.97 8.71 −8.73 6.37E-11 1.03E-07 14.77 Interleukin 18 receptor 1
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FIGURE 1 | Bacterial meningitis patients have a distinct profile on the
heatmap of the blood derived gene expression levels. The top 100
genes (vertical dimension) from the decreasing ordered list of moderated
t-values were clustered according to the distances between their gene
expression values. Signals are scaled to Z -scores of the rows. The
colored bar above the heatmap (horizontal dimension) indicates the
grouping variable—golden rod for meningitis patients (M), blue for healthy
controls (K).
pair-wise comparisons between groups were performed. The
type of pathogen significantly influenced the expression profile.
Table 3 (additional information in Table A3) illustrates gene
expression differences if S. pneumoniae or other pathogens cause
BM. The gene expression profile was significantly different in
patients with pneumococcal meningitis compared to BM caused
by other pathogens. However, the genes listed in Table 3 differ
from the genes responsible for the general effect of BM (BM
patients versus controls, see Table 2). We have to consider the
pathogen heterogeneity here. While the number of patients with
S. is 14, group with “other” pathogens is smaller (seven patients)
and very heterogeneous (almost all pathogens as single entries).
Therefore, this comparison is exploratory without any conclusive
outcome.
The clinical outcome was only modestly associated with gene
expression profiles, and there were no statistically significant dif-
ferences (p < 0.05 after FDR correction) between groups with
a favorable outcome of BM and those with a poor outcome.
However, analysis of the separate patient groups with favorable
or poor outcome in comparison with healthy controls resulted in
significant differences in gene expression profiles that probably
reflect the effect of an acute infection.
A functional annotation of expression profiles was subse-
quently applied in order to identify functional changes in the
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FIGURE 2 | The volcano plot depicting the fold differences in gene
expression levels between the bacterial meningitis patients and
healthy controls. Colored points refer to the top 100 transcripts according
to fold change (blue 612 diamonds) and p-value (red circles).
context of genetic networks. Using IPA software, the dataset con-
taining 5500 genes that had significant differential expression
between BM and control groups was uploaded. The genetic
network with the highest score (43) was related to anti-
gen presentation, cell-mediated and humoral immune response
(Table 4). Again, almost all activated networks were related to the
immune response.
Maps for the two most significantly disturbed pathways,
the antigen presentation and cellular immune response path-
ways were generated (Figures 3, 4). In the antigen presentation
pathway, the up-regulated genes were the major histocompati-
bility complex (MHC) class II region encoded HLA subgroup
genes—HLA-DR, HLA-DQ, HLA-DP. In the case of the cell-
mediated immune response pathway, the up-regulated genes
were associated with interlekins: interleukin-2 receptor subunit
beta (IL2RB), interleukin-5 receptor alpha (IL5RA), interleukin-7
receptor (IL7R).
QUANTITATIVE RT-PCR
In order to verify changes found in the microarray experiment,
qRT-PCR was performed. Genes were sorted according to the sta-
tistical significance of their differential expression and 10 genes
with the lowest p-values were selected. The following genes
were analyzed: CD177, FCER1A, CPA3, IL1R2, IL18R1, IL18RAP,
OLFM4, TLR5, IL5RA, and IL7R. In all 10 cases, qRT-PCR
Table 3 | The type of pathogen caused differences in gene expression profiles and table illustrates comparison between two groups of BM
patients, S. pneumonia vs. other pathogens.
Probeset Gene LogFC AveExpr T P-value Adjusted B-value Gene name
P-value
7893004 NA 2.20 4.68 5.84 7.71E-07 0.025 5.399
7932109 SEPHS1 0.64 7.94 5.45 2.71E-06 0.044 4.325 selenophosphate synthetase 1
7909455 TRAF3IP3 0.76 9.28 5.02 1.09E-05 0.085 3.136 TRAF3 interacting protein 3
8006634 PIGW 0.85 5.63 4.96 1.32E-05 0.085 2.966 phosphatidylinositol glycan class W
7945071 FOXRED1 0.34 6.64 4.89 1.66E-05 0.085 2.770 FAD-dependent oxidoreductase
8103867 WWC2-AS2 −0.43 5.31 −4.85 1.89E-05 0.085 2.660 WWC2 antisense RNA 2
7948894 RNU2-1 −2.29 6.85 −4.81 2.11E-05 0.085 2.563 RNA. U2 small nuclear 1
7980309 C14orf1 0.66 7.73 4.70 3.04E-05 0.085 2.251 probable ergosterol biosynthetic protein 28
8173269 LAS1L 0.63 7.04 4.63 3.83E-05 0.085 2.052 LAS1-like
8088458 FHIT 0.59 6.71 4.59 4.32E-05 0.085 1.947 fragile histidine triad gene
8008517 NME1 0.88 6.77 4.58 4.50E-05 0.085 1.914 NME/NM23 nucleoside diphosphate kinase 1
7915718 TESK2 −0.57 7.90 −4.57 4.54E-05 0.085 1.905 testis-specific kinase 2
7916020 NA −0.50 3.38 −4.57 4.55E-05 0.085 1.904
8020691 PSMA8 0.38 3.89 4.57 4.64E-05 0.085 1.887 Proteasome subunit type alpha 8
8119492 BYSL 0.51 6.88 4.54 5.05E-05 0.085 1.813 bystin-like
7899253 ZDHHC18 −0.80 10.42 −4.53 5.11E-05 0.085 1.803 zinc finger. DHHC-type containing 18
8094719 N4BP2 1.09 6.73 4.53 5.18E-05 0.085 1.791 NEDD4 binding protein 2
7892556 NA 0.76 12.28 4.52 5.39E-05 0.085 1.758
7894790 NA 0.66 9.69 4.51 5.48E-05 0.085 1.743
7978132 IPO4 0.46 7.22 4.47 6.29E-05 0.085 1.624 importin 4
7972548 GPR18 1.07 6.55 4.46 6.46E-05 0.085 1.601 G protein-coupled receptor 18
7927876 TET1 0.64 5.19 4.45 6.63E-05 0.085 1.579 tet oncogene 1
7930148 SFXN2 0.68 6.64 4.44 6.78E-05 0.085 1.560 sideroflexin 2
7903920 CHI3L2 1.30 6.05 4.44 6.81E-05 0.085 1.556 chitinase 3-like 2
8058670 IKZF2 1.27 6.10 4.44 6.86E-05 0.085 1.549 IKAROS family zinc finger 2
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Table 4 | Top 10 most significantly activated pathways.
ID Molecules in network Score Focus Top functions
molecules
1 AIM2, B3GNT5, BPI, C4, C3AR1, CARD6, CD27, CD63, CD74, CEACAM8, CLEC2D
(includes EG:29121), CRISP3 (includes EG:10321), CST7, EMR1, ETS, HLA-DMA,
HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DRA, IFN Beta, IL12, IL32,
IL18R1, IL18RAP, KLRB1, MHC Class II, MHC II, MHC II-and beta, MHC2 Alpha,
MYBL1, NFκB, PTGDR, and SOCS3.
43 26 Antigen presentation,
cell-mediated immune
response, and humoral immune
response.
2 BMX, CCR4, CD2, CD3, CD4, CD5, CD6, CD8, CD28, CD52, CD247, CD3D, CD3E,
CD3G, ERK, Fcer1, FCER1A, HDC, HSH2D (includes EG:84941), ICOS, IgE, ITK,
MERTK, MS4A2, NFATcomplex, PAG1, PDGFC, PLCgamma, PLCG1, RASGRP1,
TCR, TEC/BTK/ITK/TXK/BMX, TXK, VAV, and ZAP70.
40 25 Cell signaling, molecular
transport, and vitamin and
mineral metabolism.
3 ARG1, ARHGAP29, Calpain, CCL5, CCR7, CD3-TCR, CD40LG, CLC, CYP1B1,
FGD4, Filamin, FLOT1, GNLY, GZMB, HPR, IgG, IgM, Integrin and alpha, ITGA4,
ITGA7, ITGAM, ITGB7, Jnk, KLHL2, LRG1, MAP2K1/2, MMP, MMP8, MTF1, POR,
PRF1, Rap1, Ras homolog, SAMSN1, and Tgf beta.
36 23 Cell-to-cell signaling and
interaction, hematological
system development and
function, and immune cell
trafficking.
4 ADM, Alcohol group acceptor phosphotransferase, BCL2A1, Calcineurin protein(s),
CDC25B, Cpla2, Creb, CX3CR1, DPP4, GBA, GPR183, GZMA, hCG, HGF, HMGB2,
Hsp27, IL1RL1, LDHA, LDHB, LDL, MAP2K6, MAPK14, Mek, MKK3/6, MKNK1,
MS4A1, NFATC2, P38 MAPK, PRKCH, PRKCQ,R PS6KA5, Rsk, TNFAIP6, Vegf, and
ZAK.
35 23 Cellular compromise,
inflammatory disease, and
genetic disorder.
5 AIM2, ANKS1A, ARG1, ARG2, Arginase, BTN3A1, BTN3A2, CD163, CLEC4E,
CLEC5A, CYSLTR1, CYSLTR2, EIF1AY, GAS7, HLX, IFI44, IFI44L, IFNA2, IFNG,
IGF1, IL13, IL13RA2, IL18R1, IL18RAP, IL4R, ISL1, LCN2, MS4A4A, P2RY5,
PDLIM2, PECR, SAMSN1, SLC1A3, TRPS1, and UBD.
33 22 Antigen presentation,
cell-mediated immune
response, and humoral immune
response.
6 Akt, CD163, CR1, FLT3, GC-GCR dimer, GRB10, Ifn gamma, IKK, IL1, IL-1R,
IL-1R/TLR, IL1R1, IL1R2, IL2RB, IL5RA, IL7R, Interferon alpha, IRAK3, IRF,
JUN/JUNB/JUND, KCNA3, LCN2, NEDD4, NF-and kappa; B, ORM1, Ptk,
RARRES3, RNF125, SIGLEC5, STAT5a/b, TGFBR3, TIFA, Tlr, TLR2, and TLR5.
31 21 Cell-mediated immune
response, hematological system
development and function, and
tissue morphology.
7 ACSL1, Actin, AMPK, CASP5, Caspase, CCNA1, CCND2, Cyclin A, Cytochrome c,
DACH1, E2f, ERK1/2, Erm, GZMK, Histone h3, Hsp70, Hsp90, IFIT1, Insulin,
KCNMA1, KLRG1, MME, MMP9, NFKBIA, NLRC4, NR3C2, PFKFB3, PI3K, PPARG,
RNA polymerase II, SPN, STAT, TNFAIP3, TRAT1, and VNN1.
29 20 Cardiovascular disease,
hematological disease, and
neurological disease.
8 Ap1, ARL4C, B4GALT4, B4GALT5, CAMK4, CaMKII, CCR3, CEACAM1, CHI3L1,
Coup-Tf, ETS1, ETS2, G alphai, GADD45A, Galactosyltransferase beta 1,4, HPGD,
HRH4, LRRN3, LTF, Mapk, Myosin, Nfat, PADI4, Pak, Pdgf, PDGF BB, PFKFB2,
PLEKHA1, PP2A, Rac, Rxr, SERPINB1, THBS1, VitaminD3-VDR-RXR, and WDFY3.
26 20 Gene expression, cardiovascular
system development and
function, and cellular
movement.
9 24,25-dihydroxyvitamin D3, ACVR1B, ADCYAP1R1, ALP, ALPL, ASPH, ATP9A,
CA4, Calmodulin, CD84, CD244, Ck2, CYP19A1, CYP2D6, DDAH2, F Actin, FSH,
GPR56, LY9, Pka, Pkc(s), PLC, PRKACB, PRKACG, Proteasome, Ras, SH2D1A,
SH2D1B, SH3BP4, SLAMF6, SLAMF7, SMPDL3A, STAT4, TCF7, and UPP1.
23 17 Cell death, cancer, and tumor
morphology.
10 ATP13A3 (includes EG:79572), CALML3, CCNG2, CCR7, CD59, CD177, CD274,
CEP170, CSF3, ENTPD7, GALNT14, GYG1, IDI1, IL17F, IL1RAPL1, LRRFIP2,
MS4A5, MUC2, MUC13, MUC5AC, MYO10, NCR3, NR1D1, NR1D2, PCOLCE2,
PIGA, PLEKHA6, PRTN3, RORA, SH3BGRL2, SORL1, TGFB1, TMED8, UBE2J1,
and ZFP36.
20 15 Hematological disease, cell
death, and immunological
disease.
confirmed statistically significant changes in gene expression
between the groups (Figure 5). In BM patients, CPA3, FCER1A,
IL5RA, and IL7R were up-regulated and IL18R1, IL18RAP,
OLFM4, TLR5, CD177, and IL1R2 were down-regulated.
DISCUSSION
The significant role of the immune response in determining
the outcome of BM has been well characterized in the litera-
ture. The present exploratory study on gene profiling in patients
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FIGURE 3 | Functional analysis of the gene expression networks,
performed using Ingenuity Pathway Analysis (IPA). This figure
illustrates the activation of the antigen presentation pathway. The
genes in green were down-regulated and the genes in red were
up-regulated with respect to the healthy control group. (Numbers are
fold changes).
with BM demonstrates that activation of the host’s immune
response occurs at the level of the transcriptome. Most of
the up-regulated genes are derived from mast cells suggesting
hyper-activation of the immune system and allergic response
(Saito, 2008; Manikandan et al., 2012). However, there are still
many significantly up- or down-regulated genes which have not
been clearly associated with bacterial infections to date. As no
other genome-wide gene expression profiling studies have been
done in BM patients, we compared our results with earlier stud-
ies conducted on sepsis patients (Stone, 1994; Warren, 1997;
Hotchkiss and Karl, 2003; Nduka and Parrillo, 2009).
In the early phase of sepsis, a full-blown activation of
immune responses due to the release of high levels of damage
associated molecular patterns (DAMPs) from invading microor-
ganisms or damaged host tissue has been described. This leads
to up-regulation of TLR expression (Nduka and Parrillo, 2009).
Activation of TLR2 and TLR4 are some of the first steps in the
immune response to BM, triggering the inflammatory cascade by
the cytokines (Coimbra et al., 2006; Manikandan et al., 2012).
Our findings on a systemic response to infection are quite general
as the group of BM patients in our study was quite heterogeneous,
with a wide range of ages and infecting organisms. As a general or
common pattern for the BM, we found a significant activation of
inflammatory and immune response genes. Common or general
patterns in mammalian cell transcriptome response to pathogens
causingmeningitis have been described (Schubert-Unkmeir et al.,
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FIGURE 4 | The functional analysis of the gene expression
networks, performed using Ingenuity Pathway Analysis (IPA). This
figure illustrates the activation of the cell-mediated immune response
network. Genes in green were down-regulated and the in red were
up-regulated with respect to the healthy control group. (Numbers are
fold changes).
2009). Immune activation with up-regulation of interleukins and
interferons has been accepted as a general response to meningitis
(Schubert-Unkmeir et al., 2009). However, the results in litera-
ture and the design of these experiments are quite different. While
several studies have described activation of different components
of the immune response, other studies have used animal mod-
els or ex vivo blood samples, no systemic whole transcriptome
analysis of blood samples from BM patients has been performed
so far (Pathan et al., 2004; Schubert-Unkmeir et al., 2009; Del
Tordello et al., 2012). Therefore, our study describes a unique
approach, analyzing blood samples of BM patients for whole
genome transcription profiling.
In addition to the general pattern, we found some pathogen
specific footprints in the gene expression profile in single cases.
Cluster analysis of these gene expression profiles demonstrated
that the only case of E. coli meningitis in the 17 days old baby
(BM_19_M039) clustered within the control group (Figure 1).
Whether this is due to the fact that the blood gene expression
profile is pathogen specific or because this case occurred in a
neonate, or both, remains to be proven in larger studies. Another
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FIGURE 5 | Validation of microarray results by quantitative real-time PCR (qRT-PCR). Blue bars represent the qRT-PCR data (relative expression, Ct) and
the red bars are data from the microarray experiment. The data from the microarrays were strongly correlated with the qRT-PCR data.
case of neonatal meningitis clustering among the controls had a
new episode of BM few weeks later. This may have been indicative
of an abnormal immune response in that child. Previous antimi-
crobial therapy was not associated with clustering. Both patients
(BM_19_M039 and BM_26_M028) were children with an age less
than one month but the age cannot be the only reason for differ-
ent clustering as the third, very young patient did not show a sim-
ilar gene expression profile to BM_19_M039 and BM_26_M028.
Differential clustering was also supported in the analysis using
a linear model, where a significant effect of pathogen type was
found on the differential expression.
All the samples were collected from the patients during hos-
pitalization, during the acute phase of the disease. Therefore,
expression of the genes related to pathogen identification and
pro- and anti-inflammatory cellular signaling was expected to be
increased (Coimbra et al., 2006). In addition to common immune
system activation genes (interleukins etc.), we were able to see
quite specific hypersensitivity-related gene expression pattern,
not described for BM so far. Indeed, the three most up-regulated
genes were FCER1A, CPA3, and MS4A2, all closely related to the
early immune response and hypersensitivity. FCER1A is involved
in inducing the inflammatory and immediate hypersensitivity
responses in allergic disorders such as hay fever, asthma, and
chronic idiopathic urticaria (Bleehen et al., 1987; Bruhn, 2011;
Chandrashekhar et al., 2011; Rueff et al., 2011). FCER1A seems
to play a role in several pathways involved in both innate and
adaptive immune responses (Van Vugt et al., 1996, 1999; Ernst
et al., 1998; Edberg et al., 1999). CPA3, mast cell carboxypepti-
dase, is a distinctive carboxypeptidase which is exclusively located
in mast cells and possesses pancreatic carboxypeptidase A (CPA)-
like activity (Goldstein et al., 1989; Natsuaki et al., 1992). MS4A2
(FCER1B) plays a role in allergic or autoimmune diseases, such
like Wegener’s granulomatosis, asthma and atopic dermatitis
(Grammatikos, 2008; Mathias et al., 2009; Sanak et al., 2009).
Therefore, the list of up-regulated genes suggests a strong activa-
tion of the anaphylactic response genes and mast cells in addition
to the immune system activation. This finding could explain the
complicated clinical course of BM. Immune response factors can
be deleterious to the functions of an organism. Interleukin 6 has
been shown to causemyocardial dysfunction duringmeningococ-
cal septic shock (Pathan et al., 2004). Interestingly, activation of
mast cells is not necessary deleterious as mast cells can increase
survival in certain sepsis models (Piliponsky et al., 2008).
Similar to studies on systemic response (Schubert-Unkmeir
et al., 2009; Echenique-Rivera et al., 2011), we also observed
networks with functions including “Antigen presentation,” “Cell
signaling,” “Cell-mediated immune response,” and “Humoral
immune response” among the top activated pathways. In the anti-
gen presentation pathway, the up-regulated genes wereMHC class
II region encoded HLA subgroup genes—HLA-DR, -DQ, -DP.
The MHC-II locus consists of a group of 7–10 highly polymor-
phic genes that code for the alpha and beta chains of the classical
MHC-II heterodimeric molecules. These molecules function by
presenting antigenic peptides to CD4+ T lymphocytes and are
critical in the development of the T cell repertoire, prolifera-
tion and differentiation of antigen-specific CD4+ T cells during
adaptive immune responses. HLA-DM, also present in our path-
way aids this process, as it is a MHC class-II-associated molecule
(Majumder et al., 2006).
In the antigen presentation pathway, down-regulated genes
were IL18R1 and IL18RAP. IL18R is a key regulator of TH1
cells. Binding of IL-18 to IL-18R stimulates TH1 but also
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TH2-type cytokine release depending on its cytokine milieu. A
strong association between a single-nucleotide polymorphism
(SNP) located in IL18R1 and asthma and atopic phenotypes has
been recently observed (Reijmerink et al., 2008).
In the cell-mediated immune response pathway, the following
genes were up-regulated: IL2RB, IL5RA, IL7R. The IL2RB pro-
tein is expressed in large granular lymphocytes (LGL) in their
resting state. This beta subunit is involved in receptor mediated
endocytosis and transduces the mitogenic signals of IL2 (http://
www.genecards.org). Interleukin 5 receptor alpha (IL5RA) is an
IL5 receptor and binds to IL5. Anti-inflammatory cytokines,
including IL10, IL4, IL13, and IL5, are synthesized from Th2
immune cells. It has been found that increased expression of
IL5RA on CD34+ cells favors eosinophilopoesis and therefore
may contribute to the subsequent development of blood and
tissue eosinophilia, a hallmark of allergic inflammation (Sehmi
et al., 1997).
Some limitations of the study should be noted. Due to the rar-
ity of BM, the patients group is very small and heterogeneous
in terms of age and infecting organisms. Heterogeneity of our
study populations makes our study non-conclusive and this is
a serious limitation. Children were not included into the con-
trol group, so those two groups were not completely age-matched
and they differed in the lower quartile for age (47 and 13). Also,
heatmap (Figure 1) clearly shows that the two newborns cluster to
the controls and third newborn clusters to the meningitis group.
Therefore, we cannot exclude possible age-dependent effects.
In addition, pathogen specific subgroup analysis is also com-
plicated. In our study we mainly had patients with S. pneumoniae
and very few patients infected with other pathogens. At the
same time the “other pathogens” group was very heterogeneous.
Therefore, results from pathogen comparison should be treated
with caution.
Moreover, our analysis was based on the RNA extracted
from the whole blood, not from the enriched Peripheral Blood
Monocyte Cells (PBMCs) fraction.We acknowledge that the com-
position of the circulating blood cells in patients with BM and
healthy controls is very different and that analysis of PBMCs
would give a more focused description of the transcriptome.
However, the whole blood may even be more advantageous as
PBMCs reduce the number of neutrophils and in the case on
BM, gene expression patterns from neutrophils may dominate
the gene expression profile (Del Tordello et al., 2012; Li et al.,
2012). Therefore, the analysis of the whole blood may present
a more complete and systemic picture of changes in the blood
transcriptome.
Our findings from the genome-wide expression profiling study
indicate that there is a significant immune activation at the level
of the transcriptome in patients with BM and we suggest that this
could partly explain the complicated clinical course and poor out-
come of BM.However, these findings are not conclusive due to the
limited size and heterogeneity of our samples and should be veri-
fied in studies using a larger sample size and more homogeneous
or matched population.
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APPENDIX
Table A1 | Characteristics of the control group used in present study.
Age Sex
K003 85 Female
K004 58 Female
K005 81 Male
K006 52 Male
K007 60 Female
K008 40 Female
K009 39 Female
K010 61 Female
K011 48 Female
K012 28 Male
K013 47 Female
K014 58 Female
K015 52 Female
K016 47 Female
K018 60 Female
K020 51 Female
K024 72 Male
K027 56 Male
Table A2 | The function of the most significantly up- and
down-regulated genes described in Table 2.
Genes Function
FCER1A This gene encodes the alpha subunit of immunoglobulin
epsilon receptor (IgE receptor), what is the initiator of the
allergic response. It is found on the surface of mast cells
and basophils.
CPA3 Mast cell specific secretory granule metalloexopeptidase
that regulates innate immune response. By degrading
vasoactive peptides, CPA3 is protecting against sepsis
and reduce mortality.
MS4A2
(FCER1B)
Encodes the beta subunit of immunoglobulin epsilon
receptor (IgE receptor), what is the initiator of the allergic
response. It is found on the surface of mast cells and
basophils.
DACH1 Encodes a chromatin-associated protein that associates
with other DNA-binding transcription factors to regulate
gene expression and cell fate determination during
development.
HRB The encoded protein binds the activation domain of the
human immunodeficiency virus Rev protein when Rev is
assembled onto its RNA target.
HDC This gene encodes a enzyme that converts L-histidine to
histamine. Histamine regulates several physiologic
processes, including neurotransmission, gastric acid
secretion,inflamation, and smooth muscle tone.
(Continued)
Table A2 | Continued
Genes Function
GRB10 This gene encodes a growth factor receptor-binding
protein that interacts with insulin receptors and
insulin-like growth-factor receptors.
PAG1 The protein encoded by this gene is involved in the
regulation of T cell activation.
NR3C2 This gene encodes the mineralocorticoid receptor, which
mediates aldosterone actions on salt and water balance
within restricted target cells.
VNN1 This gene may play a role in oxidative-stress response.
MID2 The protein is member of ubiquitin-proteasome system.
IRAK3 This protein is primarily expressed in monocytes and
macrophages and functions as a negative regulator of
Toll-like receptor signaling and is associated with a
susceptibility to asthma.
IPO11 Importins mediate nucleocytoplasmic transport of protein
and RNA cargoes.
TMED8 Transmembrane emp24 protein transport domain
containing 8.
ANKRD34B A novel phosphoprotein is induced during bone marrow
commitment to dendritic cells.
PDGFC The protein encoded by this gene is a mitogenic factor for
cells of mesenchymal origin.
IL18R1 This receptor specifically binds interleukin 18 (IL18), and
is essential for IL18 mediated signal transduction,
associated with asthma.
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Table A3 | Function of genes from Table 3 (gene expression profile
related to the type of pathogen).
Genes Function
SEPHS1 This gene encodes an enzyme that synthesizes
selenophosphate from selenide and ATP.
TRAF3IP3 The gene encodes a protein that mediates cell growth by
modulating the c-Jun N-terminal kinase signal
transduction pathway.
PIGW Glycosylphosphatidylinositol (GPI) is a complex glycolipid
that anchors many proteins to the cell surface.
FOXRED1 The encoded protein is localized to the mitochondria and
may function as a chaperone protein required for the
function of mitochondrial complex I.
WWC2-AS2 WWC2 antisense RNA 2.
RNU2-1 RNU2-1 forms spliceosome what catalyzes the removal
of introns from nuclear mRNA precursors.
C14orf1 Chromosome 14 open reading frame 1 was identified as
overexpressed on pancreatic cancer cell lines.
LAS1L LAS1L interacts with the mammalian Rix1 complex to
regulate ribosome biogenesis.
FHIT This gene, a member of the histidine triad gene family is
involved in purine metabolism.
NME1 This gene (NME1) was identified because of its reduced
mRNA transcript levels in highly metastatic cells. It is
biomarker of malignancy for some tumors.
TESK2 This gene product is a serine/threonine protein kinase
what is involved in sprmatogenesis.
PSMA8 Proteasome subunit.
BYSL Bystin may play multiple roles in mammalian cells, a
conserved function is to facilitate ribosome biogenesis
required for cell growth.
ZDHHC18 Palmitoyltransferase activity.
N4BP2 This protein binds and hydrolyzes ATP, may function as a
5’-polynucleotide kinase, and has the capacity to be a
ubiquitylation substrate.
IPO4 Importins 4 and 7 accomplish nuclear import of
HIF-1alpha more efficiently than the classical importin
alpha/beta NLS receptor.
GPR18 Orphan G-protein-coupled receptor GPR18 with
N-arachidonylglycine as the endogenous ligand.
TET1 Tet methylcytosine dioxygenase 1, nuclear exclusion of
TET1 is associated with loss of 5-hydroxymethylcytosine
in IDH1 wild-type gliomas.
(Continued)
Table A3 | Continued
Genes Function
SFXN2 Proteasome related gene, associated with genetic risk for
Parkinson’s disease.
CHI3L2 The encoded protein is secreted and is involved in
cartilage biogenesis.
IKZF2 This gene is involved in the regulation of lymphocyte and
in early hematopoietic development.
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